LD-2 disclosure · 3rd Quarter - Report
ALNYLAM PHARMACEUTICALS
Client
- Description
- Biopharmaceutical company
- Location
- Massachusetts · United States of America
Registrant
- Description
- Consulting
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
1 issueMedicare/Medicaid
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Provisions related to home infusion in H.R.8816 - American Medical Innovation and Investment Act of 2024 (Rep. Buchanan), and H.R. 7623 - Telehealth Modernization Act of 2024 Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
LobbyistsJOHN MCMANUS
Covered position (JOHN MCMANUS): Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas
TargetedSENATE · HOUSE OF REPRESENTATIVES